IRCT20151227025726N15招募中3 期
Evaluation the efficacy and safety of Umifenovir (Arbidol) Administration in comparison with Lopinavir-ritonavir (Kaletra) in COVID-19 patients
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 100 years（—）
- 性别
- All
入选标准
- •Laboratory confirmed COVID-19 with RT-PCR
- •Oxygen saturation < 93%
- •Fever more than 72 hours before admission
- •Bilateral pulmonary infiltration
- •Age over 18 years old
排除标准
- •Chronic kidney disease (Stage IV and V)
- •Acute kidney injury
- •Pregnancy or breastfeeding
- •Drug allergy history
- •Chronic liver disease (Child pugh C)
- •Mild phase of COVID-19
- •Critical phase of COVID-19
研究者
相似试验
已完成
3 期
Effect of Umifenovir in treatment of covid-19IRCT20200523047550N1Tehran University of Medical Sciences50
已完成
3 期
mifenovir effectiveness in the treatment of COVID-19IRCT20200322046833N1Center for Progress and Development of Iran100
招募中
3 期
Investigating the efficacy and safety of Umifenovir in controlling the symptoms of patients with COVID-19IRCT20080901001165N46Center for Progress and Development of Iran200
招募中
3 期
Evaluation the effects of Favipiravir in COVID-19 patientsCOVID-19 pneumonia.COVID-19, virus identifiedU07.1IRCT20151227025726N14Shahid Beheshti University of Medical Sciences84
Unknown
4 期
Umifenovir in Hospitalized COVID-19 PatientsCOVID-19NCT04350684Shahid Beheshti University of Medical Sciences40